Everything below concerns GHRH receptor. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-03-04. Numbers and descriptions here follow the published literature rather than marketing material.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilized white powder | Supplied as a freeze-dried solid for research use |
| Molecular weight | Approximately 3,647 Da (DAC form) | Lower for the variant lacking the albumin-binding moiety |
| Solubility | Soluble in water and aqueous buffer | Typically dissolved in sterile or bacteriostatic water |
| Typical storage temperature | −20 °C or below | Dry powder, desiccated and protected from light |
| Common analytical method | Reversed-phase HPLC with mass spectrometry | Used for purity estimation and identity confirmation |
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
Research in Italy suggests that healthy centenarians have high levels of both vitamin A and vitamin E and that this seems to be important in causing their extreme longevity. Other research contradicts this, however, and has found that this theory does not apply to centenarians from Sardinia, for whom other factors probably play a more important role. A preliminary study carried out in Poland showed that, in comparison with young healthy female adults, centenarians living in Upper Silesia had significantly higher red blood cell glutathione reductase and catalase activities, although serum levels of vitamin E were not significantly higher. Researchers in Denmark have also found that centenarians exhibit a high activity of glutathione reductase in red blood cells. In this study, the centenarians having the best cognitive and physical functional capacity tended to have the highest activity of this enzyme. Additional research shows that people whose parents became centenarians have a higher number of naïve B cells. It is known that the children of parents who have a long life are also more likely to reach older age, but it is not clear why, although inherited genes are believed to play an important role. A variation in the gene FOXO3A is known to have a positive effect on the life expectancy of humans, and is found much more often in people living to 100 and beyond – moreover, this appears to be true worldwide. Men and women who are 100 or older tend to have extroverted personalities, according to Thomas T.
=== Applications in marketing and advertising === Industry standards now cover AI agents that plan, negotiate, and buy digital media. In 2026, the technology arm of the Interactive Advertising Bureau, IAB Tech Lab, published the Agentic Advertising Management Protocols (AAMP), an open framework for agents that discover inventory, negotiate, and complete media transactions on behalf of buyers and sellers. This differs from platform-native automation such as Google Ads Smart Bidding and Meta Advantage+, which optimize bids and delivery inside a single advertising platform. Cross-channel agents instead recommend budget changes across media, typically with a human in the loop.
== Kinetics == The rate at which organostannanes transmetalate with palladium catalysts is shown below. Sp2-hybridized carbon groups attached to tin are the most commonly used coupling partners, and sp3-hybridized carbons require harsher conditions and terminal alkynes may be coupled via a C-H bond through the Sonogashira reaction.
On May 26, Austria's domestic intelligence service reported that Iran was pursuing an advanced nuclear weapons program with ballistic missiles capable of carrying nuclear warheads over long distances. Iran rejected the intelligence report as "false and baseless", calling it an attempt to create "media hype" against Iran and lacking any credibility. Iran also denied having agreed to a three-year pause of its enrichment program. On June 2, Reuters reported that Iran was preparing to decline the US proposal. After speculation that Iran might be allowed limited uranium enrichment under a possible deal, Senator Schumer demanded that Witkoff testify before Congress to clarify whether any such side agreement existed. The administration publicly maintained that Iran would not be permitted to enrich uranium. Trump also declared firmly that the deal would prohibit it. Khamenei responded that uranium enrichment is central to Iran's nuclear program and he rejected US demands to halt it. Although the American government had suspended new sanctions on Iran on June 2, just four days later it imposed secondary sanctions on 10 individuals and 27 financial investment companies and trading firms.
Sources: en.wikipedia.org
=== Initial analogue development (1996–2014) === The development of insulin analogues began with Humalog (insulin lispro), a short-acting insulin analogue developed by Eli Lilly, which was approved by the FDA in 1996. Humalog was designed to be absorbed more quickly than regular insulin, offering improved flexibility in meal timing and postprandial glucose control. In 2000, Lantus (insulin glargine) was approved by the FDA and the European Medicines Agency (EMA). Lantus is a long-acting insulin analogue designed to provide a steady basal level of insulin throughout the day, typically lasting up to 24 hours, thereby reducing the need for multiple daily injections. In 2004, Apidra (insulin glulisine), another short-acting insulin analog, was approved by Sanofi-Aventis to improve postprandial glucose control. In 2005, Levemir (insulin detemir), developed by Novo Nordisk, was approved for clinical use. Levemir is a long-acting insulin analogue similar to Lantus but with a slightly shorter duration of action. It provides stable basal insulin coverage with a reduced risk of hypoglycemia compared to older insulins.
Mechanism The reaction of tetrazines with trans-cyclooctenes is a highly specific biorthogonal reaction recognized for its rapid reaction rates, compatibility with physiological environments, and its metal-free characteristics. Commonly referred to as tetrazine ligation, the reaction was initially reported in 2008 and has since become a widely adopted bioorthogonal chemistry tool in both in vivo and in vitro studies. The tetrazine ligation is a specific type of inverse electron demand Diels-Alder (shown in the second mechanism in Figure 13) (iEDDA) [4+2] cycloaddition. The mechanism involves an electron-deficient tetrazine, typically a substituted 3,6-diaryl-s-tetrazine functioning as the diene and an electron-rich strained alkene, typically a trans-cyclooctene (TCO) compound, serving as the dienophile (shown in Figure 14). Trans-cyclooctenes have a high strain energy of 17.9 kcal/mol due to their non-planar double bond, making it very reactive and a strong dienophile. Following the initial iEDDA, a retro-Diels-Alder (shown in the last mechanism in Figure 13) reaction occurs, resulting in the expulsion of nitrogen gas (N2), driving the reaction forward. This promotes the irreversible nature of the reaction, which enhances its suitability for bio-labeling applications. This reaction has fast reactivity at low concentrations, with second order rate constants ranging from 1–106 M−1 s−1 depending on the specific tetrazine and TCO pair.
=== Derivation === This section presents a derivation of the equation above for electrons. A similar derivation can be found for the equation for holes. Consider the fact that the number of electrons is conserved across a volume of semiconductor material with cross-sectional area, A, and length, dx, along the x-axis. More precisely, one can say:
== Possible uses in medicine == An alternative to using GnRH analogues in IVF treatments could be short-term administration of GnSAF. During IVF, the ovaries are stimulated by raising estrogen concentrations to supraphysiological levels, which prevents the mid-cycle LH surge. Premature LH surges are unfavorable during IVF as it is associated with low oocyte viability and low success rates during IVF treatment. GnSAF could be used to influence ovarian hyperstimulation syndrome. Using GnSAF would potentially eliminate the need to use human chorionic gonadotropin. Administration of GnSAF could also be used to prevent ovulation and replace exogenously administered steroids that are often perceived as being risky, or to delay the naturally premature LH surge observed in some hyperstimulated or infertile women. GnSAF could form part of a contraceptive drug or in treatments for infertility that target LH hypersecretion or abnormal ovarian cycles.
== Further reading == Müller, Rainer H.; Mäder, Karsten; Gohla, Sven (3 July 2000). "Solid lipid nanoparticles (SLN) for controlled drug delivery – a review of the state of the art". European Journal of Pharmaceutics and Biopharmaceutics. 50 (1): 161–177. doi:10.1016/S0939-6411(00)00087-4. PMID 10840199. Shah, Mansi K.; Madan, Parshotam; Lin, Senshang (June 2014). "Preparation, in vitro evaluation and statistical optimization of carvedilol-loaded solid lipid nanoparticles for lymphatic absorption via oral administration". Pharmaceutical Development and Technology. 19 (4): 475–485. doi:10.3109/10837450.2013.795169. PMID 23697916. S2CID 42174732. Shah, Mansi K.; Madan, Parshotam; Lin, Senshang (3 October 2015). "Elucidation of intestinal absorption mechanism of carvedilol-loaded solid lipid nanoparticles using Caco-2 cell line as an in-vitro model". Pharmaceutical Development and Technology. 20 (7): 877–885. doi:10.3109/10837450.2014.938857. PMID 25069593. S2CID 40506806.
Sources: en.wikipedia.org
Life is thought to have emerged from inanimate matter more than 3.5 billion years ago when a rudimentary abiogenesis process gradually evolved into an autocatalytic process capable of template-based replication. It was proposed on the basis of experimentally feasible RNA reactions catalyzed by a ribozyme, that the emergence of life was likely a gradual process involving the evolutionary properties of variation, heredity and reproduction, ultimately allowing for Darwinian evolution. Recent efforts have been directed at trying to demonstrate RNA replication under conditions that assume the presence during early evolution of plausible nucleotide intermediates and plausible environmental conditions that could favor strand replication alternating with strand separation. One such effort was the demonstration of high fidelity RNA copying using 2',3'-cyclic phosphate ligation to allow polynucleotide synthesis under conditions also compatible with strand separation. In another study, it was shown that in a model oscillating Hadean environment likely to have been abundant during early evolution, that ribozyme-mediated RNA synthesis and replication can occur. Catalysis The ability to catalyze simple chemical reactions—which would enhance creation of molecules that are building blocks of RNA molecules (i.e., a strand of RNA that would make creating more strands of RNA easier). Relatively short RNA molecules with such abilities have been artificially formed in the lab. A recent study showed that almost any nucleic acid can evolve into a catalytic sequence under appropriate selection.
=== Detection === Codeine and its major metabolites may be quantitated in blood, plasma, or urine to monitor therapy, confirm a diagnosis of poisoning, or assist in a medico-legal death investigation. Drug abuse screening programs generally test urine, hair, sweat or saliva. Many commercial opiate screening tests directed at morphine cross-react appreciably with codeine and its metabolites, but chromatographic techniques can easily distinguish codeine from other opiates and opioids. Codeine usage results in significant amounts of morphine as an excretion product. Furthermore, heroin contains codeine (or acetyl codeine) as an impurity and its use will result in the excretion of small amounts of codeine. Poppy seed foods represent yet another source of low levels of codeine in one's biofluids. Blood or plasma codeine concentrations are typically in the 50–300 μg/L range in persons taking the drug therapeutically, 700–7,000 μg/L in chronic users, and 1,000–10,000 μg/L in cases of acute fatal over dosage. Codeine is produced in the human body along the same biosynthetic pathway as morphine. Urinary concentrations of endogenous codeine and morphine have been found to significantly increase in individuals taking L-DOPA for the treatment of Parkinson's disease.
=== Neurosteroid effects === Progesterone, through the actions of neurosteroid active metabolites such as allopregnanolone and pregnanolone, is a potent positive allosteric modulator of the GABAA receptor, the major signaling receptor of the inhibitory neurotransmitter γ-aminobutyric acid (GABA). It can produce sedative, hypnotic, anxiolytic, euphoric, cognitive-, memory-, and motor-impairing, anticonvulsant, and even anesthetic effects with formation of sufficiently high concentrations of its neurosteroid metabolites and consequent GABAA receptor potentiation in the brain. These actions and effects are characteristically similar to those of other GABAA receptor positive allosteric modulators like alcohol, barbiturates, and benzodiazepines. Similarly to other GABAA receptor positive allosteric modulators like alcohol, barbiturates, and benzodiazepines, tolerance has been found to develop with exposure to increased levels of allopregnanolone and related inhibitory neurosteroids. This includes downregulation and desensitization of the GABAA receptor, reduced effects of allopregnanolone and other GABAA receptor activators (e.g., GABATooltip γ-aminobutyric acid and benzodiazepines), and rebound or withdrawal effects upon falls in allopregnanolone levels. In addition, changes in allopregnanolone levels have been implicated in adverse neuropsychiatric effects associated with the menstrual cycle (e.g., dysphoria, depression, anxiety, irritability) and postpartum period (e.g., postpartum depression), as well as in catamenial epilepsy (seizures).
Bakker sold colloidal silver supplements that he advertised as a panacea. In March 2020, the office of the Attorney General of New York ordered Bakker to cease making false medicinal claims about his supplements' alleged ability to cure the 2019–2020 strains of coronavirus, and the Federal Trade Commission and the Food and Drug Administration also sent a warning letter to Bakker about his claims regarding the supplements and coronavirus. Missouri attorney general Eric Schmitt and Arkansas attorney general Leslie Rutledge filed lawsuits against Bakker for allegedly pushing the supplements as a treatment for the virus. In the State lawsuit against him, Bakker is represented by former Missouri governor Jay Nixon, who has argued for the suit to be dismissed. Nixon says that the allegations made in the lawsuit are false, stating: "Bakker is being unfairly targeted by those who want to crush his ministry and force his Christian television program off the air." In April 2020, prohibited from receiving credit card transactions, Bakker disclosed to his viewers that his ministry was on the brink of filing for bankruptcy and urgently petitioned them for donations. The following month, GEB America and World Harvest Television dropped Bakker's program from their networks after DirecTV owner AT&T asked channels to reconsider airing the show. AT&T made the request of its channels in response to a deplatforming campaign from the liberal Christian group Faithful America. On May 8, 2020, Lori Bakker announced that Jim Bakker had suffered a stroke that his son Jay described as "minor".
Sources: en.wikipedia.org
The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.
It has not been approved by major regulatory agencies for any therapeutic indication. Material sold under this name is typically distributed for laboratory research only. Clinical use is not supported by large controlled trials.
Early human studies of the albumin-binding form reported circulation half-lives on the order of several days. The value depends on assay method and study design. Estimates for the form without the binding moiety are considerably shorter.
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.